THE IMPLEMENTATION OF PRE-EXPOSURE PROPHYLAXIS IN SPAIN WITHOUT WOMEN

The objective of this article is the succinct exposition of the exclusion of women in the resolution of July 27, 2017 in which the collaboration agreement between the Public Health General Office, Quality and Innovation and the company Gilead Servicios S.L.U. This agreement is the formalization of the entry and implementation of pre-exposure prophylaxis against HIV in the national territory. Pre-exposure prophylaxis against HIV is a novel biomedical intervention of a preventive nature applied in people who do not live with HIV that contains as a fundamental part the daily intake of a drug called Truvada, composed of two pharmacological components, emtricitabine and tenofovir, which is able to inhibit the exponential reproduction of the virus in the event of the exposure of the tissues of the virus to HIV without radically changing sexual habits.